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Abstract
This paper tries to calculate quality of life (QOL) from subjective health evaluations in
Japan following Cutler and Richardson (1997) and Groot (2000). It then extends the model
in several ways. Firstly, while previous studies deﬁne the domain of QOL in an ad hoc
manner, i.e. excluding ”excellent” or ”very poor” respondents, this paper suggests a more
rigorous alternative measure. Secondly, heterogeneity among individuals that is inevitable
in micro-data is accounted for in the estimation process. Thirdly, economic variables such as
income or job status that are considered to aﬀect subjective health status are also accounted
for. The estimation results show the following: using the same model as previous work,
similar tendencies are found, but coeﬃcients are smaller for many symptoms and diseases.
Economic variables help to clarify the eﬀect of symptoms or diseases on subjective health
evaluation. The QOL measures deﬁned in this paper are smaller for most symptoms and
diseases, and thus the measures in previous research are likely to overestimate of damage
to QOL by symtoms and diseases and may be inappropriate.JEL Classiﬁcations:
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Cost eﬀectiveness analysis has been widely used in evaluation of new medical technology
and in analysis of health policy. Though QALYs, DALYs and other methods are used to
measure outcomes, each method has issues to be clariﬁed. The Rating Scale, the Standard
Gamble and the Time Trade-Oﬀ are the most widely used methods [1].
In the Rating Scale approach, there are several ways to ask subjects to describe prefer-
ences. The scale can have numbers, categories, or a ten-centimetre line on a page. Health
states are placed between two clearly deﬁned endpoints on a line. The most preferred
health state is placed at one end and the least preferred at the other end. Though this
method is relatively easy for subjects to understand, it is subject to measurement biases.
The Standard Gamble measure asks for preference under uncertainty. Alternative 1 is
a treatment for a given health state with two possible outcomes: to live healthily for an
additional t years with probability p, and to die immediately with probability (1 − p).
Alternative 2 is to live an additional t years with the given state. Probability p is varied
until the respondent feels indiﬀerent between two alternatives, and the preference score
for the health state is p. This is based on the fundamental axioms of utility theory of
Von Neumann and Morgenstern and although theoretically justiﬁed, it is complicated for
general population to comprehend.
The Time Trade-Oﬀ method asks subjects to select from two alternatives. One is to live
with state i for t years followed by death, and the other is to live healthily for x years
(where x<t ) followed by death. x is varied until the respondent is indiﬀerent between two
alternatives. The preference for state i is x/t. This also has some minor diﬃculties [2,3].
When the focus of analysis is a whole society or other aggregate, for both technical
and cost considerations it is no longer possible to ask such complex questions. Subjective
health status analysis is an eﬃcient approach, but several issues remain. As the answer is
subjective, comparability among diﬀerent individuals is problematic, i.e. it is impossible
1to sum up across a whole society. Fortunately, surveys of this kind have been performed
over a long period, and some knowledge about bias by age and sex has been collected [3-6].
What is of more concern in evaluation of disease-related cost and medicine is adaptation
to illness. The longer a person suﬀers from a disease, the smaller is the loss caused by the
disease likely to be recognized. This tendency is not speciﬁc to this kind of model, and is
also observed in QOL evaluations involving the diﬀerence among people with and without
a disease [7].
In this paper, we try to calculate QOL from subjective health evaluation in Japan fol-
lowing Cutler and Richardson [3] and Groot [4], and then extend the model in several
ways. Firstly, while previous studies deﬁne the domain of QOL in an ad hoc manner,
i.e. excluding ”excellent” or ”very poor” respondents, this paper suggests a more rigorous
alternative measure. Secondly, heterogeneity among individuals, inevitable in micro-data,
is accounted for in the estimation process. Thirdly, economic variables such as income or
job status are used as variables.
This paper is organized as follows. In the next section, the data used in this paper are
explained, and then the proposed estimation models are shown in Section 3. The QOL
deﬁnition is shown in Section 4, and in Sections 5 and 6 the results of the estimation of
QOL are shown.
2 Data
A Living Standard Survey has been conducted every three years since 1986. The purpose
of the survey is to investigate health, medical services, pensions, welfare, incomes and other
factors aﬀecting living standards. Questionnaires consist of four parts - family, individual,
income and saving components. The number of subjects in the family and individual parts
is approximately 780,000 individuals (280,000 families), selected randomly, and that of
the income and saving surveys is approximately 120,000 individuals (40,000 families), also
2selected randomly. The data used in this study were collected in 1998.
Subjective health responses range from excellent to good, fair, poor and very poor. In
previous studies, respondents were asked to evaluate their health in comparison with their
age peers. Note that in Cutler and Richardson [23], subjective health is measured in the
opposite order.
Symptoms and diseases are surveyed in more detail than in other studies. Symptoms
are fever, fatigue, sleeplessness, irritation, failing memory, headache, dizziness, bleary eyes,
diﬃculty in seeing, tinnitus, diﬃculty in hearing, palpitation, diﬃculty in breathing, chest
pain, coughs and sputum expectoration, the sniﬄes, noisy breathing, retching, diarrhoea,
constipation, appetite lost, stomach ache, haemorrhoids, toothache, dental problems, diﬃ-
culty in chewing, rash, itching, stiﬀ shoulder, back pain, arthralgia, impairments of hands
and feet, numbness, frigid hands and feet, foot edema, disuria, frequent urination, incon-
tinence, paramenia/merorrhalgia, broken bones and sprain, wounds, and other symptoms.
The respondents mark the symptoms multiply, but the survey does not have information
about whether they have considered seeing a doctor, or the seriousness of the symptoms.
Diseases they suﬀer from and are consulting a doctor about are diabetes, obesity, hy-
perlipidaemia, diseases of thyroid gland, dementia, psychosis, neurosis, autonomic im-
balance, cataracts, retinopathy, tympanitis, deafness, hypertension, stroke, angina/AMI,
other circulatory problems, acute nasopharinxis, allergic rhinitis, asthma, other respiratory
problems, gastritis/duodentis, gastric/duodenal ulcer, hepatitis/cirrhosis, cholecytolithia-
sis/cholesystitis, other digestive problems, tooth decay, oral problems, atopic dermatitis,
contact dermatitis, urticaria, boldness, gout, chronic rheumatoid arthritis, arthritis, stiﬀ
shoulder, lumbago, osteoporosis, kidney problems, prostatic hypertropy, pre-menopausal or
post-menopausal problems, fractures, injuries and burns, anaemia/haemopathy, malignant
neoplasm, pregnancy , and others. The respondents also mark the symptoms multiply, and
they choose the one that is of most concern.
33 Models for estimation
The basic models following previous studies are as follows. The dependent variable Hi is
deﬁned to be 1 when the ith individual assesses his or her health to be excellent, 2 good,
3 fair, 4 poor and 5 very poor. The independent variables are as follows. The vector Xi
represents demographic characteristics. Di deﬁnes diseases they suﬀer and Si indicates
their symptoms. The estimation method is the ordered probit method with
H
∗
i = α0 + XiαX + DiαD + SiαS + εiɹ
Hi =

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where C1, the threshold between Hi = 0 and Hi = 1, is normalized to be 0.
Groot [4] extended the ordered probit model to explain the change in the threshold of
subjective health according to these conditions:
H
∗
i = α0 + XiαX + DiαD + SiαS + εiɹ
Hi =

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Hereafter, eq. (1) is called the constant threshold model and eq. (2) the function threshold
model.
In the following, the economic variables Ei are used in the estimation as an alterna-
tive speciﬁcation. Then all the coeﬃcients are estimated by a heterogeneity consistent
estimation method, which is appropriate for micro-data such as that used here.
44 QOL Deﬁnition
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Formulations of this kind are easy to understand, but there are some problems. Firstly,
the domain of QOL is set in an ad hoc manner, i.e. excluding ”excellent” or ”very poor”
respondents. Originally the QOL concept requires 0 to represent dead and 1 to represent
perfect health. Thus all the respondents should be less than 1 and greater than 0. However,
the previous studies assign 1 to ”excellent” and 0 to ”very poor”. This is inconsistent with
the QOL concept and QOL may thereby be overestimated.
Secondly, the denominator may be very small in comparison with the numerator, and
thus the QOL measure cannot be limited to [0,1], but it is obviously deﬁned over [−∞,∞].
Thirdly, in the constant threshold model, the QOL eﬀect of a disease is assumed to be the
same across respondents. However, there is no evidence for this and it seems to be more
natural to consider QOL to be dependent upon the health status of the respondent. For
example, the eﬀect of ﬂu is diﬀerent between healthy people and ill elderly people.
To overcome such shortcomings, a new deﬁnition of QOL is proposed in this paper as
QOLHO =Φ ( Ziˆ αZ) − Φ(Ziˆ αZ +ˆ α
j
D) (5)
5where Φ is the cumulative distribution function of the standard normal distribution. This
is favoured more when comparing to QOLc
CR,G and QOL
f
CR,G on several counts. Firstly,
QOLHO deﬁnes all the respondents without excluding ”excellent” and ”very poor”. Sec-
ondly, QOLHO is always below 1 and positive. Thirdly, QOL diﬀers among respondents
even in the constant threshold model according to their health status. Fourthly, QOL is




QOLHO which is thought to have damaging or negative eﬀects through certain symptoms
or diseases on the QOL.




CR,G deﬁnes QOL between [−∞,∞] and causes the problem mentioned
above.
Since QOLHO varies among individuals, the social or aggregate QOL is
 
[Φ(Ziˆ αZ) − Φ(Ziˆ αZ +ˆ α
j
D)]f(di) (6)
where f(·) represents the probability distribution function of individuals in this society.
5 Estimation Results
5.1 Check for Goodness of Fit
We ﬁrst need to check the goodness-of-ﬁt before evaluating the results. For the ordered
probit, especially the function threshold model, it is not obvious how to evaluate goodness-
of-ﬁt. In this paper, following Kenkel [4], the estimated distribution of the subjective health
evaluation will be compared with the actual distribution for the purposes of veriﬁcation.
While the percentages in the distribution in the actual observation show 5.44%, 13.22%,
43.94%, 32.87% and 4.51% for ”excellent” to ”very poor” respectively, the estimated ones in
the constant threshold model for all symptoms and sicknesses are 5.49%, 13.25%, 44.09%,
32.52% and 4.62%, and in the function threshold model they are 5.50%, 13.44%, 43.87%,
632.52% and 4.65%. Therefore, both are very similar and ﬁt well. As in the other estimated
model with the economic variables and the restrictive model, the results are almost the
same, so that checking for goodness-of-ﬁt is omitted so as to save space.
5.2 Constant Threshold Model
In Table 2, age is seen not to be signiﬁcant, and that females evaluate their health signiﬁ-
cantly worse than males do, which is the same result as in the UK. The number of children
makes their health evaluation better, a result opposite to that in the UK.
Concerning symptoms and diseases, almost all show worse health evaluation, although
some symptoms and diseases raise health evaluation in signiﬁcance, such as failing memory,
the sniﬄes, toothache, dental problems, wounds, hyperlipidemia, hypertension, allergic
rhinitis, tooth decay, oral problems, and stiﬀ shoulder. In the UK and USA studies, there
is no such a counter-intuitive case. Three reasons can be oﬀered in explanation.
Firstly, information of symptoms and sickness in the Japanese data set is more detailed
than in the others. If a kind of symptom or sickness is typical at an earlier stage, or
typically has co-morbidity with the others, its eﬀect would raise health evaluation.
Secondly, as this survey is conducted for the household member as explained above,
those who suﬀered a certain symptom or sickness would feel better than an inpatient.
Hence the health evaluation in this survey is contaminated by such a severe selection,
it does not reﬂect the whole impact of these symptoms and diseases. Thirdly, maybe the
most important point is that the reference group that is used by the respondents when they
evaluate their health may be falsely imagined. That is, the word ”the same age group”
is missing in the survey, though it is included in the others. Thus they may compare the
current situation with the situation when they were admitted to hospital. Currently they
are discharged and enjoying better health, even though they have not recovered completely.
In this case, biased sampling excluding inpatients causes counter-intuitive results.
75.3 The Function Threshold Model
Though Groot [4] cannot ﬁnd signiﬁcant symptoms or diseases consistently across all
threshold functions, Tables 3 indicates that there are many consistently signiﬁcant variables
such as marital status, bleary eyes, the sniﬄes, retching, appetite loss, stiﬀ shoulder(s),
back pain, paramneia/merrorhalgia, hypertension, other circulatory problems, and gastri-
tis/duadentis. Moreover the coeﬃcients for toothache, oral problems, diﬃculty in chewing,
fractures, wounds, and injuries are consistently negative but insigniﬁcant, and thus these
symptoms or diseases raise the criterion for good health.
5.4 The Model with Economic Variables
In general, economic situations other than pure health conditions also may aﬀect health-
related QOL, but the concept excludes such a non-health condition. Therefore, by esti-
mating it using economic variables, we can control and eliminate the eﬀect of economic
conditions and thus measure the pure health related QOL. If not, the estimated QOL is
biased by the economic situation.
Table 4 shows the results. Though it shows that aging signiﬁcantly reduces subjective
health evaluation, many vriables are almost the same as the number in Table 2. On
the other hand, in the function threshold model summarized in Table 5, the number of
signiﬁcant variables in the threshold function decreases. Only bleary eyes, the sniﬄes,
retching, back pain, broken bones and sprain, hypertension, and other circulatory problems
are consistently signiﬁcant in the threshold function.
5.5 Restrictive Estimation Comparing the UK and USA
Since the data set in Japan is more detailed than for the UK or the USA, as mentioned above
comparison among countries may be aﬀected. To control for this problem, a restrictive
model that includes only variables comparable with the UK and USA study as explanatory
variables is performed in this subsection.
8In the constant threshold model summarized in Table 6, cataracts, hypertension, allergic
rhinitis, atopic dermatitis, and contact dermatitis remain as counter-intuitive results in
which these diseases raise subjective health evaluation. On the other hand, the function
threshold model in Table 7 shares results with the non-restrictive model, which means that
there are many consistently signiﬁcant variables in the threshold function, except for the
sniﬄes.
To sum up, such a restriction does not have much eﬀect and thus the more detailed
information in Japan does not cause counter-intuitive phenomena.
6 Estimation Results for QOL
Table 8 summarizes the QOL. In the case of diabetes, we observe 0.86 in the UK, 0.66
in the USA, and 0.954 in Japan. For hypertension, while it is 0.86 in USA, it is 1.004 in
Japan.
Conversely, the QOL values for diﬃculty in seeing are 0.93, 0.92 and 0.985, and diﬃculty
in hearing are 0.93, 0.97 and 0.996 in USA, UK and Japan, respectively. In some symptoms
or diseases, the QOL among countries are almost the same. However, for most symptoms
or diseases, QOLs are higher in Japan than in UK and USA.
Next, Table 9 shows QOL in the function threshold model. For diabetes , we observe
0.85 for the UK and 0.942 for Japan, and for diﬃculty of seeing, 0.94 for the UK and 0.979
for Japan. Hence, even in the function threshold model, the QOL in Japan is higher than
in UK and USA.
Estimation results with economic variables can isolate pure QOL which is not aﬀected
by such economic conditions, but these are not considered in the existing literature. The
QOL in the constant threshold model is shown in Table 10, and the function threshold
model in Table 11. Though the number of signiﬁcant coeﬃcients decreases, QOL is not so
much aﬀected by introducing economic variables; for instance in the case of diabetes, it is
90.955 in both models.
QOLHO, our original QOL deﬁnition which is to be [0,1] by deﬁnition, is also shown in the
tables. In comparison with Cutler and Richardson [3] and Groot [4], QOL
f
CR,Gs are adjusted
for the loss of QOL by certain of symptoms or diseases, 1 − QOL
f
CR,G. Overall, QOLHO
is smaller than 1 − QOL
f
CR,G. For instance, in the case of diabetes, while 1 − QOL
f
CR,G is
0.059, QOLHO is only 0.015. In the case of hypertension, 0.032(1−QOL
f
CR,G) is compared
to 0.009(QOLHO). In other words, this discrepancy indicates the possibility of systematic
overstimation of damage to QOL in the existing literature because of appropriateness of
QOLHO as discussed above.
7 Concluding Remarks
This paper applies the same procedure as in the existing literature to Japan, and then
improves upon it. Firstly, while the previous studies deﬁne the domain of QOL in an ad
hoc manner, i.e. excluding ”excellent” or ”very poor” respondents, this paper suggests a
more rigorous alternative measure. Secondly, heterogeneity among individuals, which is
inevitable in micro-data, is accounted for in the estimation. Thirdly, economic variables
such as income or job status that are considered to aﬀect subjective health status are also
accounted for. The estimation results show that in the same model as the previous ones,
similar tendencies are found, but coeﬃcients are smaller for many symptoms and diseases.
Economic variables help to clarify the eﬀect of symptoms or diseases on subjective health
evaluation. The damage of QOL by symtoms and diseases deﬁned in this paper is smaller
for most symptoms and diseases, and thus the measures in the previous research are likely
to overestimate it and may be inappropriate.
Finally, we make suggestions for further research. As emphasized above, the most impor-
tant diﬀerence between Japan and others appears to be the lack of the phrase ”comparison
with the same age group.” This lack seems to contaminate the result heavily. To overcome
10this problem, a survey including such a phrase should be performed. Moreover, longer
macro QOLs should be calculated for evaluating health care.
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13Table1. Average of Variables
Symptoms and  Others Diseases
subjective health 1.917984 diabetes 0.0762411
age 44.27781 obesity 0.0130053
age
2 2701.441 hyperlipidemia 0.0748662
female 0.5602294 thyroid gland disease 0.0180939
age*female 25.46679 dementia 0.0061259
age
2*female 1578.155 psychosis 0.0106469
marital status 0.6403086 neurosis 0.017179
number of children 0.5552163 autonomic imbalance 0.0224535
fever 0.0312671 cataract 0.0787169
fatigue 0.1377711 retinopathy 0.018363
sleeplessness 0.0952363 tympanitis 0.0137637
irritation 0.0812276 deafness 0.0236669
failing memory 0.133876 hypertension 0.23321
headache 0.1161468 stroke 0.0340399
dizziness 0.0699599 angina/AMI 0.0486011
bleary eyes 0.1787417 other circulatory problems 0.038326
difficulty in seeing 0.1334128 acute nasopharinxis 0.0267641
tinnitus 0.0947807 allergic rhinitis 0.0410514
difficulty in hearing 0.1188347 asthma 0.0343922
palpitation 0.0924953 other respiratory problems 0.0260693
difficulty in breathing 0.0745687 gastritis/duodentis 0.0333695
chest pain 0.0444178 gastric/duodenal ulcer 0.0424116
coughs and sputum 0.1548852 hepatitis/cirrhosis 0.0240877
the sniffles 0.1181969 cholecytolithiasis/cholesystitis 0.010642
noisy breathing 0.0555488 other digestive problems 0.0293672
retching 0.1074151 tooth decay 0.1158393
diarrhoea 0.0347446 oral problems 0.0515711
constipation 0.1163898 atopic dermatitis 0.0346515
appetite loss 0.0336284 contact dermatitis 0.0217
stomach ache 0.069474 urticaria 0.0144732
hemorrhoids 0.0283287 baldness 0.0018104
toothache 0.0827917 gout 0.0164108
dental problems 0.0656928 chronic rheumatoid arthritis 0.0185979
difficulty in chewing 0.0895113 arthritis 0.0668565
rash 0.0546149 stiff shoulder 0.0920402
itching 0.1298822 back pain 0.1430927
stiff shoulder 0.285109 osteoporosis 0.0339763
lumbago 0.3278792 kidney disease 0.0208242
arthralgia 0.219234 prostatic hypertrophy 0.0163423
dysfunction of hands and feet 0.117263 pre/post menopausal problem 0.007677
numbness 0.127908 fractures 0.0170713
frigid hands and feet 0.0917512 injuries 0.0207361
foot oedema 0.0847431 anaemia/haemopathy 0.0181575
disuria 0.0340005 malignant neoplasm 0.0093405
frequent urination 0.073278 pregnancy 0.0084305
incontinence 0.0283135 others 0.0574328
paramenia/merorrhalgia 0.0202044 unknown 0.0033272
broken bones and sprain 0.0462401
wounds 0.0155272
other symptoms 0.0616534
14Table 2. Estimation for All Diseases and Symptom using Constant Threshold Model
Symptoms and Others Diseases
age 0.0012754 diabetes 0.1697026
＊＊＊
age



































bleary eyes -0.0055684 angina/AMI 0.1450976
＊＊＊
difficulty in seeing 0.0545099
＊＊＊ other circulatory problems 0.1633805
＊＊＊
tinnitus 0.0102757 acute nasopharinxis 0.1090831
＊＊＊





difficulty in breathing 0.1193986





coughs and sputum 0.0877521







retching 0.0180103 other digestive problems 0.2106226
＊＊＊
diarrhoea 0.0434183
＊＊ tooth decay -0.1682704
＊＊＊
constipation 0.0625886
＊＊＊ oral problems -0.0556608
＊＊＊
appetite loss 0.3303635
＊＊＊ atopic dermatitis -0.0430956
＊＊
stomach ache 0.1926602
＊＊＊ contact dermatitis -0.1232689
＊＊＊






difficulty in chewing -0.0077916 chronic rheumatoid arthritis 0.423467
＊＊＊
rash 0.0192724 arthritis 0.0616562
＊＊＊
itching -0.0624505
＊＊＊ stiff shoulder -0.0488696
＊＊＊
stiff shoulder 0.0163343






＊＊＊ kidney disease 0.3458195
＊＊＊
dysfunction of hands and feet 0.3514808
＊＊＊ prostatic hypertrophy 0.0695951
＊＊＊
numbness 0.1933389
＊＊＊ pre/post menopausal problem 0.0827177
＊＊＊

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































18Table4. Estimation Result for Constant Threshold Model Including Economic Variables














































＊＊ other circulatory problems 0.1709842
＊＊＊
employee(government) -0.0289478 acute nasopharinxis 0.0895221
＊＊＊
part-time employee -0.061145




















＊＊＊ other digestive problems 0.2006465
＊＊＊
bleary eyes -0.0027497 decayed tooth -0.1518817
＊＊＊
difficulty in seeing 0.0554029
＊＊＊ oral problems -0.0600077
＊＊＊
tinnitus 0.0179138 atopic dermatitis -0.0367474









coughs and sputum 0.0864311
＊＊＊ chronic rheumatoid arthritis 0.4298735
＊＊＊
the sniffles -0.0051721 arthritis 0.0595476
＊＊＊
noisy breathing 0.0914565
＊＊＊ stiff shoulder -0.0431522
＊＊＊
retching 0.0243291






＊＊＊ kidney disease 0.3401546
＊＊＊
appetite loss 0.3087564
＊＊＊ prostatic hypertrophy 0.0683069
＊＊＊
stomach ache 0.2058353























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































difficulty in seeing 0.1776396
＊＊＊ 0.9497273 0.0645748
coughs and sputum 0.1594266
＊＊＊ 0.9548817 0.0580028
















































urticaria 0.0068883 0.9980506 0.0025148













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































26Table8. QOL Estimation for All Diseases and Symptoms using Constant Threshold Model
Symptoms 1-QOLCR,G QOLHO Diseases 1-QOLCR,G QOLHO
fever 0.059303 0.075313 diabetes 0.046056 0.058622
fatigue 0.096052 0.120863 obesity -0.00715 -0.00913
sleepless 0.045297 0.057663 hyperlipidemia -0.01719 -0.02194
irritation 0.033482 0.042686 thyroid gland disease 0.005964 0.007617
failing memory -0.01807 -0.02307 dementia 0.140866 0.174261
headache 0.042554 0.054192 psychosis 0.130733 0.162438
dizziness 0.041909 0.053375 neurosis 0.061297 0.077815
bleary eyes -0.00151 -0.00193 autonomic imbalance 0.064292 0.081567
difficulty in seeing 0.014794 0.018888 cataract -0.00328 -0.00418
tinnitus 0.002789 0.003562 retinopathy 0.028983 0.036968
difficulty in hearing 0.003878 0.004954 tympanitis -0.01043 -0.01332
palpitation 0.032997 0.042071 deafness 0.018827 0.024033
difficulty in breathing 0.032404 0.041317 hypertension -0.00361 -0.00461
chest pain 0.045865 0.058381 stroke 0.10224 0.128395
coughs and sputum 0.023815 0.03039 angina/AMI 0.039378 0.050169
the sniffles -0.00603 -0.0077 other circulatory problems 0.04434 0.056452
noisy breathing 0.031841 0.040602 acute nasopharinxis 0.029604 0.037758
retching 0.004888 0.006243 allergic rhinitis -0.0202 -0.02578
diarrhoea 0.011783 0.015047 asthma 0.05501 0.069916
constipation 0.016986 0.021685 other respiratory problems 0.063835 0.080996
appetite loss 0.089658 0.113033 gastritis/duodentis 0.020255 0.025854
stomach ache 0.052286 0.066486 gastric/duodenal ulcer 0.032797 0.041817
hemorrhoids 0.007301 0.009324 hepatitis/cirrhosis 0.059466 0.075517
toothache -0.01757 -0.02243 cholecytolithiasis/cholesystitis 0.00426 0.00544
dental problems -0.00925 -0.01181 other digestive problems 0.057161 0.072622
difficulty in chewing -0.00211 -0.0027 tooth decay -0.04567 -0.05813
rash 0.00523 0.00668 oral problems -0.01511 -0.01929
itching -0.01695 -0.02164 atopic dermatitis -0.0117 -0.01494
stiff shoulder 0.004433 0.005662 contact dermatitis -0.03345 -0.04265
lumbago 0.021993 0.028069 urticaria -0.00414 -0.00528
arthralgia 0.024349 0.031069 baldness -0.04004 -0.051
dysfunction of hands and feet 0.095389 0.120053 gout -0.00216 -0.00275
numbness 0.052471 0.066719 chronic rheumatoid arthritis 0.114925 0.143688
frigid hands and feet 0.013786 0.017602 arthritis 0.016733 0.021362
foot oedema 0.024258 0.030953 stiff shoulder -0.01326 -0.01693
disuria 0.022006 0.028085 back pain 0.046598 0.059307
frequent urination 0.012793 0.016336 osteoporosis 0.051951 0.066063
incontinence 0.014456 0.018458 kidney disease 0.093853 0.118175
paramenia/merorrhalgia 0.015309 0.019546 prostatic hypertrophy 0.018888 0.02411
broken bones and sprain 0.009553 0.0122 pre/post menopausal problem 0.022449 0.028649
wounds -0.04235 -0.05394 fractures 0.041051 0.052289
other symptoms 0.044435 0.056572 injuries -0.0013 -0.00166
anaemia/haemopathy 0.033818 0.043114




27Table9. QOL Estimation for All Diseases and Symptoms using Function Threshold Model
Symptoms 1-QOLCR,G QOLHO Diseases 1-QOLCR,G QOLHO
fever 0.01357 0.003095 diabetes 0.05949 0.015016
fatigue 0.120523 0.033164 obesity -0.00756 -0.00188
sleepless 0.040255 0.009862 hyperlipidemia 0.009384 0.002423
irritation 0.044769 0.01109 thyroid gland disease 0.032302 0.008433
failing memory -0.01417 -0.00355 dementia 0.11168 0.025108
headache 0.056717 0.014421 psychosis 0.106217 0.025262
dizziness 0.061645 0.015684 neurosis 0.075285 0.019367
bleary eyes 0.018629 0.004731 autonomic imbalance 0.081881 0.020934
difficulty in seeing 0.021005 0.005148 cataract 0.010289 0.002599
tinnitus -0.00276 -0.00068 retinopathy 0.038826 0.009714
difficulty in hearing 0.013151 0.003314 tympanitis -0.01083 -0.00268
palpitation 0.05825 0.015036 deafness -0.00131 -0.00031
difficulty in breathing 0.021866 0.005297 hypertension 0.032298 0.0085
chest pain 0.053733 0.013312 stroke 0.098555 0.02479
coughs and sputum 0.041984 0.01088 angina/AMI 0.065054 0.017229
the sniffles 0.018259 0.004664 other circulatory problems 0.09043 0.024729
noisy breathing 0.041137 0.010415 acute nasopharinxis 0.04477 0.011627
retching 0.041175 0.010843 allergic rhinitis 0.001652 0.000428
diarrhoea 0.026596 0.006742 asthma 0.080179 0.021025
constipation 0.034544 0.008675 other respiratory problems 0.035888 0.008363
appetite loss 0.037997 0.008708 gastritis/duodentis 0.052371 0.013777
stomach ache 0.090601 0.024516 gastric/duodenal ulcer 0.055827 0.014685
hemorrhoids 0.040871 0.010595 hepatitis/cirrhosis 0.077306 0.020237
toothache -0.02674 -0.00652 cholecytolithiasis/cholesystitis 0.004058 0.001011
dental problems -0.01797 -0.00439 other digestive problems 0.083615 0.021963
difficulty in chewing -0.01441 -0.00346 tooth decay -0.03808 -0.00961
rash 0.003631 0.00089 oral problems 0.013876 0.003606
itching -0.01647 -0.00409 atopic dermatitis 0.00758 0.001855
stiff shoulder 0.033846 0.00897 contact dermatitis -0.02278 -0.00573
lumbago 0.049813 0.013189 urticaria -0.01288 -0.00313
arthralgia 0.039881 0.010085 baldness -0.05983 -0.01404
dysfunction of hands and feet 0.080958 0.01938 gout -0.01049 -0.00259
numbness 0.045763 0.011106 chronic rheumatoid arthritis 0.111025 0.027724
frigid hands and feet 0.011582 0.002807 arthritis 0.022893 0.005725
foot oedema 0.045446 0.011379 stiff shoulder 0.00105 0.000268
disuria 0.015154 0.003627 back pain 0.053605 0.01346
frequent urination 0.007873 0.001936 osteoporosis 0.05746 0.014365
incontinence 0.014719 0.003602 kidney disease 0.086704 0.021136
paramenia/merorrhalgia 0.0567 0.015039 prostatic hypertrophy 0.045493 0.012259
broken bones and sprain -0.01808 -0.00424 pre/post menopausal problem 0.046067 0.012346
wounds -0.05293 -0.01273 fractures 0.009542 0.002173
other symptoms 0.036929 0.008733 injuries -0.02462 -0.00579
anaemia/haemopathy 0.049165 0.012522




28Table10. QOL Estimation Including Economic Variables using Constant Threshold Model
Symptoms 1-QOLCR,G QOLHO Diseases 1-QOLCR,G QOLHO
fever 0.059919 0.076094 diabetes 0.044791 0.057028
fatigue 0.096359 0.121256 obesity -0.00765 -0.00978
sleepless 0.046258 0.058883 hyperlipidemia -0.01339 -0.01709
irritation 0.033677 0.042937 thyroid gland disease 0.010771 0.013756
failing memory -0.0205 -0.02616 dementia 0.143473 0.177321
headache 0.04266 0.05433 psychosis 0.129895 0.161489
dizziness 0.043545 0.055451 neurosis 0.06089 0.077312
bleary eyes -0.00074 -0.00095 autonomic imbalance 0.064633 0.082003
difficulty in seeing 0.014922 0.019053 cataract -0.0082 -0.01047
tinnitus 0.004825 0.006163 retinopathy 0.029116 0.03714
difficulty in hearing 0.002591 0.00331 tympanitis -0.01103 -0.01409
palpitation 0.033637 0.042887 deafness 0.018783 0.023979
difficulty in breathing 0.028715 0.03663 hypertension -0.00658 -0.00841
chest pain 0.04574 0.058228 stroke 0.097209 0.122293
coughs and sputum 0.023279 0.029708 angina/AMI 0.037481 0.047767
the sniffles -0.00139 -0.00178 other circulatory problems 0.046052 0.058622
noisy breathing 0.024632 0.031433 acute nasopharinxis 0.024111 0.030769
retching 0.006553 0.008369 allergic rhinitis -0.02079 -0.02653
diarrhoea 0.009641 0.012313 asthma 0.053437 0.067943
constipation 0.014655 0.018713 other respiratory problems 0.064378 0.081684
appetite loss 0.083158 0.105043 gastritis/duodentis 0.016502 0.02107
stomach ache 0.055438 0.070462 gastric/duodenal ulcer 0.027956 0.035664
hemorrhoids 0.011637 0.014862 hepatitis/cirrhosis 0.053583 0.068126
toothache -0.01563 -0.01996 cholecytolithiasis/cholesystitis -0.0032 -0.00409
dental problems -0.00805 -0.01029 other digestive problems 0.054041 0.068703
difficulty in chewing -0.00178 -0.00228 tooth decay -0.04091 -0.05211
rash 0.009292 0.011867 oral problems -0.01616 -0.02064
itching -0.01811 -0.02312 atopic dermatitis -0.0099 -0.01264
stiff shoulder 0.005356 0.006841 contact dermatitis -0.03184 -0.04061
lumbago 0.021184 0.027039 urticaria -0.00506 -0.00646
arthralgia 0.024992 0.03189 baldness -0.04783 -0.06087
dysfunction of hands and feet 0.094844 0.119405 gout -0.00695 -0.00888
numbness 0.05327 0.067732 chronic rheumatoid arthritis 0.115779 0.144737
frigid hands and feet 0.013294 0.016976 arthritis 0.016038 0.020477
foot oedema 0.024015 0.030646 stiff shoulder -0.01162 -0.01484
disuria 0.022208 0.028345 back pain 0.04757 0.060541
frequent urination 0.01125 0.014367 osteoporosis 0.044211 0.056294
incontinence 0.012654 0.016159 kidney disease 0.091615 0.115451
paramenia/merorrhalgia 0.02128 0.027162 prostatic hypertrophy 0.018397 0.023486
broken bones and sprain 0.011695 0.014935 pre/post menopausal problem 0.025749 0.032855
wounds -0.03382 -0.04313 fractures 0.049252 0.062665
other symptoms 0.04201 0.053508 injuries 0.009049 0.011557
anaemia/haemopathy 0.035455 0.045195




29Table11. QOL Estimation Including Economic Variables using  the Function Threshold Model
Symptoms 1-QOLCR,G QOLHO Diseases 1-QOLCR,G QOLHO
fever 0.058038 0.006672 diabetes 0.044791 0.012757
fatigue -0.01265 0.033001 obesity -0.00765 -0.00276
sleepless 0.011049 0.008905 hyperlipidemia -0.01339 0.002507
irritation 0.050939 0.009662 thyroid gland disease 0.010771 0.011994
failing memory 0.12965 -0.0033 dementia 0.143473 0.026213
headache 0.133056 0.015306 psychosis 0.129895 0.029547
dizziness 0.079353 0.014639 neurosis 0.06089 0.018018
bleary eyes 0.095256 0.004552 autonomic imbalance 0.064633 0.021703
difficulty in seeing 0.009374 0.004641 cataract -0.0082 0.002098
tinnitus 0.048389 0.000673 retinopathy 0.029116 0.010774
difficulty in hearing -0.02288 0.001605 tympanitis -0.01103 -0.00499
palpitation 0.007014 0.015745 deafness 0.018783 0.001505
difficulty in breathing 0.030866 0.005633 hypertension -0.00658 0.007173
chest pain 0.098092 0.013801 stroke 0.097209 0.021502
coughs and sputum 0.065572 0.010698 angina/AMI 0.037481 0.015293
the sniffles 0.097877 0.005361 other circulatory problems 0.046052 0.023839
noisy breathing 0.049672 0.005004 acute nasopharinxis 0.024111 0.011409
retching -0.00352 0.009527 allergic rhinitis -0.02079 -0.0008
diarrhoea 0.082999 0.002561 asthma 0.053437 0.019164
constipation 0.038184 0.006558 other respiratory problems 0.064378 0.007801
appetite loss 0.049845 0.006731 gastritis/duodentis 0.016502 0.011515
stomach ache 0.05947 0.023432 gastric/duodenal ulcer 0.027956 0.014003
hemorrhoids 0.073798 0.010344 hepatitis/cirrhosis 0.053583 0.016812
toothache 0.000658 -0.00574 cholecytolithiasis/cholesystitis -0.0032 0.000145
dental problems 0.084401 -0.0029 other digestive problems 0.054041 0.019447
difficulty in chewing -0.04071 -0.00147 tooth decay -0.04091 -0.00895
rash 0.011332 0.00038 oral problems -0.01616 0.002594
itching 0.006694 -0.00355 atopic dermatitis -0.0099 0.001446
stiff shoulder -0.02607 0.007678 contact dermatitis -0.03184 -0.00584
lumbago -0.0128 0.012957 urticaria -0.00506 -0.00275
arthralgia -0.07389 0.008761 baldness -0.04783 -0.01511
dysfunction of hands and feet -0.02356 0.018089 gout -0.00695 -0.00508
numbness 0.119398 0.011128 chronic rheumatoid arthritis 0.115779 0.026137
frigid hands and feet 0.02493 0.002818 arthritis 0.016038 0.005465
foot oedema 0.000736 0.011265 stiff shoulder -0.01162 0.000165
disuria 0.05421 0.00417 back pain 0.04757 0.011937
frequent urination 0.047186 0.003087 osteoporosis 0.044211 0.010283
incontinence 0.085216 0.003449 kidney disease 0.091615 0.017926
paramenia/merorrhalgia 0.043653 0.013384 prostatic hypertrophy 0.018397 0.010399
broken bones and sprain 0.053573 -0.00614 pre/post menopausal problem 0.025749 0.012888
wounds 0.02964 -0.00959 fractures 0.049252 0.00598
other symptoms -0.01246 0.007747 injuries 0.009049 -0.00259
anaemia/haemopathy 0.035455 0.010022
malignant neoplasm 0.076399 0.015039
pregnancy 0.028204 0.002267
others 0.02808 0.007997
unknown 0.101515 0.013973
30